Microbot Medical (MBOT) investor relations material

Executive summary

• Achieved first commercial revenues of $105,000 from the LIBERTY® Endovascular Robotic System in limited market release for Q1 2026, following FDA clearance in September 2025 and full market launch in April 2026.

• Net loss for Q1 2026 was $3.7 million, compared to $2.6 million in Q1 2025, reflecting increased commercialization and operating expenses.

• Maintains strong liquidity with $72.5 million in cash and marketable securities as of March 31, 2026, sufficient to fund operations for over 12 months.

• Focus remains on expanding commercialization, scaling manufacturing, and advancing R&D for future product candidates.

Financial highlights

• Revenue for Q1 2026 was $105,000, up from $0 in Q1 2025, driven by initial sales of the LIBERTY® system.

• Gross profit was $2,000, with a gross margin of 1.9% for Q1 2026.

• Research and development expenses decreased to $1.3 million in Q1 2026 from $3.0 million in Q1 2025, due to increased government grants and capitalization of manufacturing costs.

• Sales, general and administrative expenses rose to $1.5 million in Q1 2026 from $1.6 million in Q1 2025, reflecting higher payroll and commercialization costs.

• Net cash used in operating activities was $5.1 million in Q1 2026, compared to $4.0 million provided in Q1 2025.

Outlook and guidance

• Full market release of the LIBERTY® Endovascular Robotic System began in April 2026, with expectations for revenue growth as commercialization expands.

• Management anticipates continued net losses as investments in commercialization and R&D persist.

• Sufficient liquidity is expected to support operations for more than one year; additional capital may be raised as needed.